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ARTIGO
Introduc on
Cryoglobulins are immunoglobulins that precipitate at low temperatures and redissolve a er rewarming1–8. Brout et al classiﬁca on, based on
the clonality of the immunoglobulins, presents a good correla on between clinical manifesta ons and associated e ologies5,6. Type I are pure
monoclonal immunoglobulins, usually IgG or IgM and are essen ally associated with B-cell-prolifera ve disorders. Type II consists of polyclonal
IgG with monoclonal IgM. Type III cryoglobulins are a mixture of polyclonal IgG and IgM1,2,4–7. Types II and III are generally referred to as
mixed cryoglobulinemias and present rheumatoid factor ac vity. They develop secondarily to infec ons (most importantly hepa  s C virus –
HCV), autoimmune or neoplas c disorders1–6,8. Table 1 presents some of the clinical condi ons/agents that may be associated with
cryoglobulinemia. When no e ology is iden ﬁed the cryoglobulinemia is designated as essen al2,4,5,7.
Cryoglobulins can cause  ssue damage either by hyperviscosity or by vascular inﬂamma on mediated by immune complex deposi ons and
complement ﬁxa on1,4,5. Type I cryoglobulinemia pa ents tend to present clinical manifesta ons related to complica ons of hyperviscosity
whereas types II and III pa ents usually display manifesta ons caused by small-medium vessel vasculi s - Cryoglobulinemia vasculi s
(CryoVas)1,4–7.
It is believed that 2% to 50% of the pa ents develop symptoms5.Furthermore, clinical expression is extremely variable as CryoVas can involve a
variety of  ssues (skin, kidneys, joints, lungs, peripheral nerve system or gut) with symptoms that can range from mild (arthralgia) to fulminant
life-threatening (widespread vasculi s)1,2,6,8. Meltzer triad – purpura, arthralgia and fa gue - is present in 25% to 80%1,5,6. The skin is the
most frequently damaged organ (55% to 100% of the pa ents) with palpable purpura of the lower extremi es as the most frequent sign1,2,5,6.
Raynaud’s phenomenon (RF) and acrocyanosis can occur and evolve to digital ulcera on / acral ischaemia1,2,5,6,8.
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RESUMO
Crioglobulinas são imunoglobulinas que precipitam a baixas temperaturas e redissolvem após reaquecimento, potencialmente causando uma
forma rara de vasculite - CryoVas. A Infecção pelo vírus da Hepa te C é a principal causa de CryoVas, mas muitas outras e ologias têm sido
iden ﬁcadas. Ocasionalmente não se iden ﬁca qualquer causa e ológica e a crioglobulinémia é designada como essencial. Descrevemos um
caso de apresentação invulgar de crioglobulinémia  po II, sob a forma de fenómeno de Raynaud com isquémia acral. Apesar de nenhuma
e ologia ter sido iden ﬁcada o tratamento sintomá co permi u a cura das úlceras digitais. Os autores têm como objec vo destacar a forma
de CryoVas não associada ao vírus de Hepa te C. À medida que vão surgindo novas opções terapêu cas para o vírus C, a CryoVas tornar-se-á
um distúrbio ainda mais raro, diﬁcultando o diagnós co.
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Case Descrip on
A 63-year-old female was referred to an Internal Medicine consulta on for possible autoimmune disease. She had a 3-month history of
extremally painful digital ulcers, beginning in winter, complica ng a RF that started 2 years before. Previous Vascular Surgery consulta on had
ruled out thromboangii s obliterans (Buerger’s disease) a er extensive study. There was no clinical improvement with smoking cessa on. RF
was biphasic and symmetrical to both hands and feet. The pa ent also referred involuntary weight loss and fa gue. She reported no other
symptoms.
The pa ent had a past medical history of hypertension and depression under treatment with losartan 50 mg q.b., clomipramine 25 mg q.b.,
and aspirin 100 mg q.b..
Physical examina on revealed severe ulcera on of the distal phalanx of the second right ﬁnger with bone exposure (ﬁgure 1) and small
punctate necrosis of the distal phalanx of the third right and le  ﬁngers (ﬁgure 2 – le  ﬁnger). None of the ulcera ons were infected but all
were extremely painful. The remaining clinical observa on was unremarkable.
Laboratory results showed a rheumatoid factor of 27 UI/mL (reference range < 20 UI/mL) and the presence of cryoglobulins compa ble with
cryoglobulinemia type II: 0.9 mg/dL of polyclonal IgG and 4.5 mg/dL of monoclonal IgM. Nailfold capillaroscopy revealed giant capillaries,
capillary hemorrhages, and mild disorganiza on of the capillary architecture (ﬁgure 3).
Complete blood cell count, serum biochemistry (including complement C3 and C4), urinalysis and thyroid hormonal studies were normal. Clinical
relevant serologies were nega ve namely HCV, hepa  s B virus (HBV), human immunodeﬁciency virus 1 and 2 (HIV 1 and 2) and Interferon
Gamma Release Assay (IGRA). Serologic tests for autoan bodies were nega ve including an -Ro/SSA and an -La/SSB an bodies (an -Sjögren’s
syndrome related an gen A and B), ANA (an -nuclear an body), ANCA (an -neutrophil cytoplasmic an bodies), APS (an phospholipid
syndrome an bodies) and ACPA (an -citrullinated protein an bodies). No suspicious lesions were iden ﬁed in computed tomography of the
neck, chest, abdomen and pelvis as well as in the PET-scan (positron emission tomography). Bone marrow biopsy revealed no abnormali es.
No life-threatening organ damage and no associated e ology was found. Essen al type II cryoglobulinemia was assumed and symptoma c
treatment was directed to the RF and pain relief. Amlodipine 10 mg, pentoxifylline 400 mg, naproxen 250 mg where started, as well as cold
temperature avoidance, use of gloves and skin hydra on. A er 2 months, the small digital ulcers had healed and the largest one cured a er 6
months (ﬁgures 4 and 5) with no recurrence a er 1 year. Serologies were repeated and remained nega ve.
Discussion
HCV is the predominant cause of CryoVas, accoun ng for roughly 80% of the cases1–4,6,7,9. This iden ﬁca on allowed a be er understanding of
the disorder1,10. However, as the associa on was only iden ﬁed in 199111, most previous studies report results of heterogeneous popula ons
(with or without HCV)2,6,7and most recent studies derive from HCV-posi ve popula ons. Thus, data on presenta on, therapeu c management
and prognosis of non-HCV CryoVas pa ents is limited3,4. Ini ated in 2010, the French CryoVas survey (a na onal retrospec ve study) has
brought some new insight on non-HCV CryoVas2,3,7.
Essen al cryoglobulinemia (EC), as was the case of our pa ent, accounts for nearly 10% of all pa ents (up to 25% in non-HCV popula ons)4,5.
Mostly, therapeu c management of CryoVas takes into considera on the underlying disease, the predominant e opathogenic mechanism
(vasculi s vs hyperviscosity) and the severity of the disease1,2,4,9,10. In EC, the absence of e ology and popula on-orientated studies implies
that the best therapeu c management has yet to be deﬁned and treatment usually just involves symptoma c relief2. Mild-to-moderate
CryoVas treatment may include res ng, cold temperature avoidance, nonsteroidal an -inﬂammatory drugs, colchicine and disulone (dapsone
and ferrous oxalate)2,4,8. Severe CryoVas can be treated with a combina on of cor costeroids, immunosuppressants (rituximab,
cyclophosphamide, azathioprine or mycophenolate mofe l) or therapeu c plasma exchange2,4,5,8. Considering that our pa ent did not present
any severe organ damage, conserva ve treatment directed to RF was our op on.
CryoVas presents signiﬁcant morbidity and mortality10. Prognosis relates to vital organ damage, underlying disease and comorbidi es2,4,5,7,8.
Generally pa ents have a worse 10-year survival rate than general popula on with 15% developing life-threatening complica ons, although
roughly half of the pa ents never develop vital organ involvement5,8.
CryoVas is already considered a rare disorder despite the absence of adequate epidemiological studies1,5,8. With the development of new
therapeu c op ons for HCV, prevalence of the disorder will eventually decline even further. This case report highlights the importance of
awareness of non-HCV CryoVas and the management of these pa ents.
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Digital ulcera on
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Small punctate necrosis
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Nailfold capillaroscopy
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Evolu on
Figura V
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Evolu on
Figura VI
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Table 1 – List of condi ons that may be associated to cryoglobulinemia(5,6); * - Associated with cryoglobulinemic exacerba on.
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